Yohei Furumoto

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin et al. · Gastroenterology · 2023 · 92 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

David T. Rubin, Jessica R. Allegretti, Julián Panés et al. · The Lancet · 2024 · 83 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +15

Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis

Yohei Furumoto, Toru Asano, Tomonori Sugita et al. · BMC Gastroenterology · 2015 · 30 citations · Full text

Life Sciences, Immunology, Pathology +17

Endoscopic Detachable Snare Ligation Improves the Treatment for Colonic Diverticular Hemorrhage

Katsumasa Kobayashi, Yohei Furumoto, Daisuke Akutsu et al. · Digestion · 2019 · 29 citations

Medicine, Clinical Sciences, Surgery +16

<i>ITPA</i> gene variation and ribavirin‐induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin

Miyako Murakawa, Yasuhiro Asahina, Hiroko Nagata et al. · Hepatology Research · 2017 · 18 citations

Pharmacy, Genetics, Pharmacotherapy +17